NCT03890068 - Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

December 30, 2023

Study Completion Date

May 30, 2024

Conditions

Soft Tissue Sarcoma

Interventions

DRUG

Anlotinib Hydrochloride

48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1) or unacceptable toxicity.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou